We propose a novel technical, regulatory, and cultural solution to support research on COVID- 19 and establish the open infrastructure required to respond to the next pandemic: ICEES+ COVID-19. The proposed work will build on the prior work that our team has been engaged with as part of the Biomedical Data Translator program (?Translator?), funded by the National Center for Advancing Translational Sciences (NCATS), to research and develop the Integrated Clinical and Environmental Exposures Service (ICEES). ICEES represents a unique, disease-agnostic framework and approach to support open sharing of and research on sensitive patient data that have been integrated at the patient and visit level with public exposures data. Importantly, ICEES has been validated in the context of our initial driving use case on asthma. We will extend this effort to instantiate an ICEES+ COVID-19 open infrastructure, focused on patients at UNC Health who have been tested (positive or negative) for COVID-19. The proposed work will leverage not only our prior Translator work, but also new work that our team has been engaged with as part of the NCATS Center for Data to Health (CD2H) National Covid Cohort Collaborative (N3C). Indeed, the North Carolina Translational and Clinical Sciences Institute (home to UNC?s CTSA) was selected by CD2H leadership to lead the technical implementation of significant portions of the N3C initiative. We will adopt the N3C COVID-19 consensus phenotype for the proposed work and extend the captured data fields to include relevant data fields that were intentionally excluded by the N3C collaborative in their effort to promote uniformity and participation, but are available via our local clinical data warehouse, such as temperature, oxygen saturation, isolation flags, and other potentially relevant clinical features (e.g., blood type). We also have partnered with investigators affiliated with the Environmental Polymorphisms Registry at the National Institute for Environmental Health Sciences and will be exposing data on their registry participants. Our overall aims are to develop and deploy ICEES+ COVID-19, apply ICEES+ COVID-19 to support research on COVID-19, and promote widespread use of ICEES+ COVID-19, largely through our engagement with the Translator program, CD2H N3C, and other large-scale collaboratives. A key aspect of the proposed work is that ICEES+COVID-19 will be open source, which will allow other institutions to rapidly adopt our approach and expose their data for open analysis of COVID-19 data by a much larger community. Collectively, the proposed work will catalyze efforts to respond to the COVID-19 pandemic and position society to be better prepared for the next one.

Public Health Relevance

The proposed ?ICEES+ COVID-19? represents a novel technical, regulatory, and cultural solution to openly share otherwise sensitive patient data that have been integrated with public environmental exposures data of relevance to the COVID-19 pandemic. As an open framework and approach, ICEES+ COVID-19 will democratize research on COVID-19, serve as an exemplar for adoption elsewhere, and support preparedness for the next pandemic.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR002489-03S4
Application #
10158906
Study Section
Program Officer
Chang, Soju
Project Start
2020-06-01
Project End
2022-02-28
Budget Start
2020-08-03
Budget End
2021-02-28
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wang, Nan; Vendrov, Kimberly C; Simmons, Brian P et al. (2018) Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. Prostaglandins Other Lipid Mediat 134:24-31
Buse, John B; Garg, Satish K; Rosenstock, Julio et al. (2018) Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care 41:1970-1980
Wang, Tiansheng; Hong, Jin-Liern; Gower, Emily W et al. (2018) Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care 41:1998-2009
Gruber, Joann F; Becker-Dreps, Sylvia; Hudgens, Michael G et al. (2018) Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries. Epidemiology 29:867-875
Chun, Lani S; Vekariya, Rakesh H; Free, R Benjamin et al. (2018) Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Front Synaptic Neurosci 10:2
Sun, Xuezheng; Shan, Yue; Li, Quefeng et al. (2018) Intra-individual Gene Expression Variability of Histologically Normal Breast Tissue. Sci Rep 8:9137
Fioretto, Paola; Del Prato, Stefano; Buse, John B et al. (2018) Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab 20:2532-2540
Inscoe, Christina R; Platin, Enrique; Mauriello, Sally M et al. (2018) Characterization and preliminary imaging evaluation of a clinical prototype stationary intraoral tomosynthesis system. Med Phys 45:5172-5185
Gallaher, Jared R; Banda, Wone; Lachiewicz, Anne M et al. (2018) Colonization with Multidrug-Resistant Enterobacteriaceae is Associated with Increased Mortality Following Burn Injury in Sub-Saharan Africa. World J Surg 42:3089-3096
Buglak, Nicholas E; Jiang, Wulin; Bahnson, Edward S M (2018) Cinnamic aldehyde inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in Zucker Diabetic Fatty rats. Redox Biol 19:166-178

Showing the most recent 10 out of 76 publications